Press Releases
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
-
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Spotlight

A decade in Duchenne: Stories from the community
As the Duchenne community marks 10 years since the first U.S. FDA approval of a treatment for Duchenne, people living with the disease, family members, advocates and clinicians share their stories in their own words. Read their perspectives on the experiences that have shaped them and what they're focused on today.
Highlights
Our FDA-Approved Treatments
Learn more about our FDA-approved treatments.
A Day in The Life at Sarepta
Hear from employees and how our mission drives their work.
